Carcinoembryonic Antigen (CEA) - what it’s good for ✅ & what it’s not 🚫
CEA is not a screening or diagnostic test for colorectal cancer (CRC). Its real value is in monitoring known CEA-secreting cancers (especially CRC) for treatment response and recurrence. Many benign conditions and several other cancers can also raise CEA, so results must be interpreted in clinical context.

What CEA is 🧬

Glycoprotein (~180–200 kDa) involved in cell adhesion during fetal life; expression is low in healthy adults.
Units: ng/mL ≡ μg/L (same thing).
Half-life: ~3–7 days ➜ after curative surgery, CEA should trend down toward normal within ~4–6 weeks if no residual disease.

Typical reference ranges 📏

Non-smokers: 0–2.5 ng/mL (μg/L)
Smokers: often slightly higher, up to ~5 ng/mL
“Elevated”: >5 ng/mL is commonly flagged (assay- and lab-specific; always check your lab’s range).

Tip: Always try to use the same laboratory/assay for serial monitoring-inter-assay differences can shift values.

When to order CEA (the useful use-cases) 🎯

Before CRC surgery/therapy: Establish a baseline (prognostic & helps future comparisons).
After curative CRC resection: Serial monitoring to detect recurrence (trend matters more than a single value).
Metastatic CRC on treatment: Track response alongside imaging and clinical review.
Medullary thyroid carcinoma (MTC): Follow alongside calcitonin (CEA can rise with tumor dedifferentiation).

Not recommended for general population screening or as a one-off “cancer check.”

How to interpret a rise 📈

Trends & doubling time: A confirmed upward trend across ≥2–3 measurements is more concerning than a single bump. Faster “CEA doubling time” can suggest more aggressive or recurrent disease.
Rule of thumb thresholds (CRC):
- Persistently >10 ng/mL → higher suspicion for recurrence/metastases (but not diagnostic).
- >20 ng/mL → often associated with metastatic disease, especially to the liver-yet false positives exist.
Non-producers: A subset of CRCs do not make CEA-levels may stay normal despite active disease.

What else elevates CEA? (Cancer & non-cancer) 🧩

Cancers: Colorectal (most common use), pancreatic, gastric, cholangiocarcinoma, lung, breast, ovarian, liver, medullary thyroid, prostate.
Benign: Heavy smoking, chronic liver disease/cholestasis, pancreatitis, inflammatory bowel disease, peptic ulcer disease, COPD, infections, hypothyroidism (usually mild elevations).

Pearl: Because the liver clears CEA, cholestasis/liver mets can raise values independently of tumor burden.

Follow-up cadence (typical CRC practice) ⏱️

After curative resection: many protocols check CEA every 3–6 months for 2–3 years, then every 6 months to 5 years (integrated with clinical review and appropriate imaging/colonoscopy). Use local/national guidelines.

Performance at a glance 🔎

Diagnosis/screening: Limited sensitivity/specificity → not recommended.
Recurrence detection: Moderate sensitivity; best as part of a multimodal follow-up strategy (history, exam, imaging, colonoscopy).
Prognosis: Very high pre-op levels may correlate with worse outcomes in CRC, but management decisions hinge on comprehensive staging and pathology.

Pre-analytical & assay caveats ⚠️

Biotin supplements (high-dose) can interfere with some immunoassays → pause 24–48h if safe, per lab guidance.
Hemolysis/lipemia/assay drift can affect results-interpret alongside clinical picture and imaging.
If a result seems discordant, repeat and confirm with the same lab before acting.

Bottom line 🧠

CEA is a monitoring tool, not a stand-alone cancer test. Use it to follow known CEA-secreting tumors-especially colorectal cancer-prefer trends over single values, and always interpret in context of symptoms, exam, imaging, and histology.

Reference ranges (recap) 📚

Non-smokers: 0–2.5 ng/mL (μg/L)
Smokers: up to ~5 ng/mL may be seen
“Elevated” threshold: commonly >5 ng/mL (check your lab)

Carcinoembryonic antigen (CEA)